Therapy of schizophrenia in the course of time;Schizophrenietherapie im wandel der zeit

Psycho

Volumn 28, Issue 10, 2002, Pages 539-543

  Rüther, Eckart ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Aripiprazol; Atypical antipsychotics; Dopamine serotonine system stabilization; Next generation antipsychotic; Partial agonism; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

BODY WEIGHT DISORDER; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; HYPERPROLACTINEMIA; LONG QT SYNDROME; NEGATIVE SYNDROME; SCHIZOPHRENIA; SHORT SURVEY; WEIGHT GAIN;

EID: 0036423443     PISSN: 03407845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Bender S, Grohmann R, Engel R, Rüther E. Adverse reactions to neuroleptic drugs results from the AMSP study. Pharmacopsychiatry 2002, im Druck
2. Burris K, Molski T, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca F, Molinoff P. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther, im Druck
3. Carson WH, Stock E., Saha AR, Ali M, McQuade RD, Kujawa MJ, Ingenito G. Safety and Tolerability Meta-analysis of Aripiprazole in Schizophrenia. Posterpräsentation auf dem AEP-Kongress 2002, Stockholm
4. Casey ED, Saha AR, Ali M, Jody D, Kujawa M, Stock E, Ingenitpo GG. Switching to Aripiprazole Monotherapy. Posterpräsentation auf dem APA-Kongress 2002, Philadelphia
5. Goldstein LE, Sporn J, Brown S. New onset diabetes mellitus and diabetic ketoacidosis associated with onlanzapine treatment. Psychosomatics 1999; 40: 438-443
6. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277: 137-143
7. Jody D, Saha A, Iwamoto T, Biswas D, Lin CY, Marcus R, McQuade R. Meta-analysis of Weight effects with Aripiprazol. Posterpräsentation auf dem APA-Kongress 2002, Philadelphia
8. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur Neuropsychopharm 2001; 11(suppl 3): S268
9. Kern RS, Cornblatt B, Carson WH, Stock E, Saha AR, Ali MW, Ingenito G, Green MF. Neurocognitive Effects: Aripiprazole vs Olanzapine in Stable Psychosis. Posterpräsentation auf dem AEP-Kongress 2002, Stockholm
10. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 7-4-4-(2,3-Dichlorophenyl)-1-Piperazinyl-Butyloxy-3, 4-Dihydro-2(1H)-Quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonist actibvity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329-336
11. Kujawa M, Saha A, Ingenito G, Ali M, Luo X, Archibald DG, Phil M, Carson WH. Aripiprazole for Long Term Maintenance Treatment in Schizophrenia. Posterpräsentation auf dem APA-Kongress 2002, Philadelphia
12. Lieberman JA, Carson WH, Saha AR, Stringfellow JC, Archibald DG, Kujawa MJ, Iwamoto T. Meta-analysis of Efficacy of Aripiprazole in Schizophrenia. Posterpräsentation auf dem APA-Kongress 2002, Philadelphia
13. Stahl S. Dopamine system stabilizers, Aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" action at the dopamine receptors. J Clin Psychiatry 2001; 62: 84-842
14. Stock E, Saha A, Brunell R, Archibald DG, Phil M, Iwamoto T, Mc Quade RD. Meta-analysis of Cardiac Safety with Aripiprazole. Posterpräsentation auf dem APA-Kongress 2002, Philadelphia